Modulation of High-Density Lipoprotein Function via Cardiac Rehabilitation
Autor: | Seimi Satomi-Kobayashi, Tatsuro Ishida |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Male medicine.medical_treatment 030204 cardiovascular system & hematology chemistry.chemical_compound 0302 clinical medicine High-density lipoprotein Rehabilitation Cardiac Rehabilitation Anticholesteremic Agents Middle Aged Cholesterol efflux capacity Prognosis Cholesterol Editorial Modulation cardiovascular system Cardiology lipids (amino acids peptides and proteins) Original Article Female Lipoproteins HDL Cardiology and Cardiovascular Medicine Acute coronary syndrome medicine.medical_specialty 03 medical and health sciences Text mining Internal medicine Internal Medicine medicine Humans Acute Coronary Syndrome Aged Retrospective Studies business.industry Aryldialkylphosphatase Biochemistry (medical) Cholesterol HDL nutritional and metabolic diseases medicine.disease 030104 developmental biology chemistry Physical therapy Apolipoprotein A1 Paraoxonase-1 activity business Function (biology) Biomarkers Follow-Up Studies |
Zdroj: | Journal of Atherosclerosis and Thrombosis |
ISSN: | 1340-3478 |
Popis: | Aims: We evaluated whether exercised-based cardiac rehabilitation (CR) can ameliorate the HDL function, i.e., cholesterol efflux capacity (CEC) and paraoxonase-1 activity in patients with acute coronary syndrome (ACS). Methods: This study is a retrospective analysis of stored serum from patients with ACS following successful percutaneous coronary intervention. The CEC, measured by a cell-based ex vivo assay using apolipoprotein B-depleted serum and 3H-cholesterol labeled macrophages and arylesterase activity (AREA) at the onset or early phase of ACS, and the follow-up periods were compared between 69 patients who completed the five-month outpatient CR program (CR group) and 15 patients who did not participate and/or dropped out from CR program (non-CR group). Results: Apolipoprotein A-I (apoA-I) and CEC significantly increased by 4.0% and 9.4%, respectively, in the CR group, whereas HDL-cholesterol and AREA were not changed during the follow-up periods in both groups. Among CR patients, the CEC significantly increased, irrespective of the different statin treatment, while HDL-cholesterol and apoA-I significantly increased in patients treated with rosuvastatin or pitavastatin. Although CEC and AREA were significantly correlated each other, there is a discordance between CEC and AREA for their correlations with other biomarkers. Both CEC and AREA were significantly correlated with apoA-I rather than HDL-cholesterol. Changes in CEC and those in AREA were significantly correlated with those in apoA-I (rho = 0.328, p = 0.002, and rho = 0.428, p < 0.0001, respectively) greater than those in HDL-cholesterol (rho = 0.312, p = 0.0042, and rho = 0.343, p = 0.003, respectively). Conclusions: CR can improve HDL function, and it is beneficial for secondary prevention. |
Databáze: | OpenAIRE |
Externí odkaz: |